Bridging the Gap: Index Volume [International Conference on AIDS (12th: 1998: Geneva, Switzerland)]

Amplicor, anti-HIV 11

12th World AIDS Conference

--Keyword

Abstract -

of three versions of the HIV-1 monitor test with new gag
/Linear range of Roche HIV-1 Monitor assay using ultra
tion of an experimental DNA PCR assay for the detectio
he ultra sensitive Roche HIV-1 MonitorT assay/Multi-cen
V) DNA detection using CMV test in a cohort of HIV-posit
hly sensitive method for amplification of HIV-2 DNA/Highly sensiti
bacavir (1592, ABC)/ amprenavir (141W94) therapy in HIV-1 inf

/3TC/Phase 2 study of
ic drug interactions with
y with abacavir (1592),
g injecting drug users in
progression to AIDS?/
tis B vaccine cohorts in
esidual injecting risk in
among ethnic groups in
d non-deprived areas in
ms in Vancouver versus
dinal analyses from the
mass in HIV+ patients/, a novel protease inhibitor, in
/Pharmacokinetic drug interac, and Combivir' in subjects wit
Amsterdam: Cumulative incidence, deter
cohort study: Presence of the,New York and San Francisco
is often deliberate and preven,The Netherlands/HIV preval
/Drug users and HIV-infected
/A comparison of active injecti
cohort/T-cell renewal capacit
Anabolic steroids, resistance exercise an

2

mone produces striking anabolic effects in an HIV-infected adoles
r among gay men using steroids in central London gyms/
ctable indicator of BCM anabolism or catabolism/Viral load respo
gos, Nigeria/Sickle cell anaemia and the risk of HIV infection in La
mething that isn't there/ Anal intercourse without ejaculation as a s
atterns of unprotected anal intercourse (UAI) among men having

nonymous unprotected intercourse in London's gay backroo
ncidence of high-grade squamous intraepithelial lesions amo
veness of screening for squamous intraepithelial lesions in HI
e in UAIC (unprotected intercourse with casual partners) amo
on the natural history of human papillomavirus infection/Effec
ng rates of unprotected intercourse among San Francisco ga
ndon, UK/Unprotected intercourse among gay men and their
unprotected receptive intercourse for 15- to 22-year-old Afric
unprotected receptive intercourse for 15- to 22-year-old men
se to HIV?/Changes in sexual practice among Australian gay
on rules for unprotected sex/Gay men's strategic use of bathh
f Reality~ condoms for sex by HIV-seronegative US gay/bise
the female condom for sex/Experiences of 100 men who hav
roblem of unprotected intercourse (UAI) among men who ha
nd a second nucleoside analog during pregnancy/Combination th
ion/Double nucleoside therapy in patients with acute/prim
on with new nucleoside analogs in nucleoside experienced subjec
both wild-type and new of HIV-1 protease/A resistance s
eceiving nucleoside analogue (NRTI) therapy at 24 weeks [Stu
py naive or nucleoside experienced HIV-1 infected pati
oth the multinucleoside resistance mutation Q151M and
polymeric adamantane /Inhibition of HIV-1 replication by
detection of nucleoside resistance in a HIV-infected pae
I guanine phosphonate /Anticytomegaloviral activity and
RT) adherence/Visual scale (VAS) to assess the difficu
eration of recombinant analogues of the C-C chemokine RANTE
vir, with two nucleoside /Efficacy and safety of the com
activation of nucleoside in the presence of hydroxyurea
ation of two nucleoside as initial antiretroviral therapy:
vir plus two nucleoside in the treatment HIV infection in
ng/Long-term effects of androgen administration in men with AIDS
HIV-infectioninchildren/ Anemia associated with HIV-infection in c
in in AIDS patients with anemia and MAC infection/The efficacy of
fe in AIDS patients with and MAC infection/Hematocrit, sy
y HIV-infected skin-test anergic and non-anergic adults from a vol
I RNA copies in sera of patients with HIV disease/Compa
SIV-infected monkeys/ Anergy and dysfunction of CD4+ and Vy2
y in the diagnosis of TB/ testing: Questionable utility in the
n/Lack of usefulness of anergy panel and PPD to diagnose tuberc
/Stability of cutaneous in women with or at risk for HIV infe
k independent factor for in HIV infection/Viral load: Risk ind
hysiologic monitoring in aneurysm and surgery/Intraoperative neu
apy (HAART)/Bacillary angiomatosis in the setting of clarithromy
e conjunctiva/Bacillary of the conjunctiva/Bacillary
clinical study/Bacillary in HIV-infected patients - A
mass (BCM) and phase angle after discontinuation of human growt
ring 1996 and 1997: An Anglo-French comparison/Uptake of com
wellbeing in Latina and Anglo AIDS caregivers/Stress and wellbei
olgus Macaques as an animal model to evaluate vaginal microbici
r JE-2147 (KNI-764) in animals /Pharmacokinetics and oral bioav
alence and follow-up of anogenital oncogenic human papillomavir
/Characterization of the anonimous testing center users/Characte
ackrooms and saunas/ Anonymous unprotected anal intercourse
r HIV/AIDS in Thailand/ counselling and testing clinic
ervice at the Awanama ( ) Clinic/Pre 2nd post test cou

41145
41146
41155
42143
60622
41158
286*/12204
12321
12389
32328
12291
13321
13357
23193
23518
32431
33385
60796
32185
32179
60811
60517
33207
14313
14204
14218
22302
22307
23109
23114
23116
23119
23120
23139
23413
23520
33128
33133
33303
463*/12152
12198
125*/12203
555*/41212
22343
22386
32296
41205
41220
60291
60535
11101
12336
42262
60411
60671
32176
32161
32141
60149
13324
60721
31169
60632
13257
31209
60816
60016
22114
22123
42256
32182
42289
24306
33156
42273

22314
34179
14218
33290
43149

SKeyword Abstr
smitted disease (STD)/ anonymous HIV testing and counselling cl
in Germany - Unlinked testing of newborns 1993-19
s in Slovenia/Unlinked HIV prevalence monitoring in
eterosexuals attending test sites in Switzerland/Fact
s in women undergoing HIV counseling in Brazil/Gen
ted women seeking an counselling/testing service in
A decade of'educating " "about HIV/AIDS: Lessons le
nt centers for HIV/AIDS testing (CTA) - Alternative ap
em (IVRS)/Unlinked & counselling to the general pu
ngary/Evaluation of an HIV screening and counsellin
ulation that is seen on a testing site/Comparison of th
suits from the unlinked neonatal surveys through 19
on in French centers of and free detection/Motivation

act -

nd HIV-1 shedding from anorectal
women attending urban antenatal
g HIV testing in a British
or syphilis screening of
d opt-out HIV testing in
re/A national survey of
or HIV antibodies in an

mucosa/Antiretroviral therapy a
clinics in C6te d'lvoire, 1997/Pr
setting/Reasons for declining HI
and STD clinic attenders in Guy
care: Uptake and acceptability i
HIV screening policy and practic
clinic in the southern China/Chi

1

e relative importance of antepartum antiretroviral therapy versus i
son concept and AIDS: Anthropological analysis of bioethics in m
nts/Anti-cardiolipin and anti-/ 2 glycoprotein I in HIV positive patie
ve work of the Estonian Anti-AIDS Association during 7 years/Pre
an Association "Krilija"/ activity of the St. Petersburg Ga
rmenia/Peculiarities of anti-AIDS program aimed at teenagers in
munity perception/HIV anti-body test, a community perception/H
nhibitors have a direct anti-Candida effect by inhibition of Candid
acterial biopolymers for anti-candidiasis vaccines construction/U
n HIV positive patients/ Anti-cardiolipin and anti-/2 glycoprotein I
HIV-1-infected patients/ Anti-chemokine antibodies in sera of HIVT despite termination of anti-CMV therapy/Containment of CMV re
neventful interruption of maintenance therapy in respond
nalyzed with 3 different anti-CXCR-4 monoclonal antibodies/Role
ubjects: Inhibition by anti-Fas antibodies and type-1 cytokines I
y in HIV-infected adults/ Anti-GM 2 mediated cytotoxic antibody in
immunotherapy using anti-gp 41 human monoclonal antibody del
bitor of HIV-1 protease/ Anti-HIV-1 activity of and HIV-1 resistance
ged albumins and AZT/ activity of combinations and co
e multimeric ribozymes/ gene therapy using packageabl
/The new Cobas Core /2 EIA DAGS II: A highly sensitiv
ort IV]/Durable clinical anti-HIV-1 activity (72 weeks) and tolerabili
ganglioside GM2 as an agent/Human IgM monoclonal
mplete enhancement of CTLm responses in advanced i
ns/Induction of specific IgY produced in species pathog
etection of antibodies /2: Capillus HIV-1/HIV-2/Rapid
STD prevention/In vitro and HIV-2 virucidal properties o
elopment of VLP-based vaccine/Biomolecular and phyl
HIV-2 lentivirusdelivery/ Anti-HIV chemokines: Domain mapping a
uorocytidine (D-D4FC)/ activity, biochemistry, and pharm
of the CXCR4 receptor/ activity of AMD3465, a novel anta
new type I interferon/ and immunomodulatory effects o
acokinetics, safety and anti-HIV activity/Oral PMPA pro-drug: Rel
Double or triple therapy:A Brazilian dillema/Double or trip
man serum/Synergistic activity of ritonavir and other prote
anolide A/Combination interactions and resistance profile
up of people asking for antibody testing for preventive re
hesis/Impact of potent therapy on T helper cell homeosta
ents treated with potent therapies/Early up-regulation of
te d'lvoire/Presence of antibodies in cervicovaginal fluid
mediated by a CD8+ cell response/Protection of HIV-expo
T-cell cytotoxicity/New function: RANTES activity via CC
lamivudine-containing regimen/HBs seroconversion of
ourage compliance with treatments/The development of e
nd selection of active agents for the development of vag
aneously submitted to testing at an AIDS unit (Casa da A
120: Potential pitfalls of ELISA using saliva/Interactions o
r: Combined testing for and HIVAg within 18 minutes/HIV
ger proteins/Targeting agents to nucleocapsid protein zi
combination with other agents/Adefovir (PMEA) and PM
Characterization of the properties, resistance profile and
d characterization of an substance from Perilla frutescens
s, chiral separation and activity of enantiomeric oxaselen
x HIV recombinant and -2 assays to distinguish between
der for quality control of test/Evaluation of microplate ELI
ononuclear cells during therapies/The change of HIV-1 pr
gs/Cost and efficacy of drugs/Cost and efficacy of
ddA), a uniquely stable drug, in adults with symptomatic
arrier/Brain delivery of drugs: Rapid screening using an i
rived antibody against /Parametric and non-parametric e

1

13152
13187
13189
23359
23464
33275
33295
33322
139*/33473
43150
60095
60549
60769
23393
13111
23472
33241
43120
43136
60897
23292
60463
60761
60001
60595
33554
43148
31211
31219
60761
31161
22260
32242
60161
21160
60458
41243
12270
41188
41247
42108
12359
31112
112*/31124
41239
42113
60370
60715
11104
557*/41174
41183
41186
12211
12245
12315
12366
13472
219*/21169
21180
23515
31143
31148
32118
32394
33144
33278
162*/41101
163*/41102
41187
41195
41196
41197
41200
42121
42132

42174
42254
42263
42270
43485